GLP-1 Supply Crunch
Gilad Lotan@gilgul
· 1
−1.0%
since Oct 1
The idea
I believe GLP-1 demand is outrunning the world's ability to manufacture it, and the bottleneck is in production, not the drugs themselves. So instead of betting on the drugmakers, this basket owns the layers behind them: pen and component makers, sterile fill-finish capacity, the firms building new production lines, and the purification and QC tools that whole process depends on. I'm holding some cash to add on pullbacks, and I'd rethink this if oral pills start replacing injectors as the dominant form.
What it owns
- Every injectable dose needs a pen, needle, stopper, and cartridge, and these makers are the ones sold out. · West Pharmaceutical ServicesIt makes the elastomer stoppers and plungers that go into every GLP-1 injection, components that drug makers qualify years in advance and switch away from slowly., Stevanato GroupIt manufactures the pens and glass cartridges that hold the injectable doses, capacity that remains booked out as long as pen demand stays ahead of supply., Becton DickinsonIt is the largest maker of pen needles, so rising injection volumes translate directly into needle sales at the scale only it can match., EmbectaIt manufactures injection needles as its primary business, the most direct way to own exposure to rising injection volumes.28%
- Filling the drug into pens under sterile conditions is the tightest single constraint on supply. · Thermo Fisher ScientificIt operates sterile fill-finish lines for hire, the exact capacity constraint that drug makers are racing to lock up through long-term contracts., DanaherIt sells the filtration and bioprocessing equipment that goes into every new sterile manufacturing line, collecting revenue as capacity expands., CorningIt manufactures pharmaceutical-grade glass vials and cartridges for drug filling, supply that takes years to add and remains tight during volume growth., Sotera HealthIt operates a large share of sterilization capacity for pens, needles, and components, regulated capacity that is hard to build and must expand with injection volumes.23%
- Billions in new plants are being built right now, and these firms automate, wire, and construct them. · ATS CorporationIt builds the automated assembly lines for injector pens and has won public contracts to do so, benefiting as pen capacity constraints drive new equipment orders., Comfort Systems USAIt constructs the cleanrooms and mechanical systems inside new sterile pharmaceutical plants, work that grows directly with the GLP-1 manufacturing buildout., EMCOR GroupIt performs the electrical and mechanical installation work in large pharmaceutical plant construction, feeding directly off the GLP-1 capacity expansion wave., Jacobs SolutionsIt engineers and designs new pharmaceutical plants from the start of each project, winning work early in the capacity race and signaling whether the buildout continues.20%
- Every batch of peptide has to be purified and tested, so tool makers sell more as volumes climb. · RepligenIt supplies purification tools for peptide manufacturing at industrial scale, the chemistry equipment needed as GLP-1 production volumes expand., WatersIt makes the analytical instruments that test every batch of GLP-1 drug for purity before release, so more plants and more batches mean more instrument sales and consumables., Agilent TechnologiesIt sells laboratory instruments for GLP-1 research and production quality control, benefiting from both pipeline development and manufacturing ramp-up spending., AvantorIt supplies the high-purity chemicals and materials consumed daily as GLP-1 plants run, so revenue tracks production volume rather than one-time construction.19%
- Cash10%